Sector News

Sanofi parts ways with Oxford BioMedica on hemophilia tie-up inked by Bioverativ

March 20, 2021
Life sciences

Just a few weeks after Sanofi agreed to purchase Bioverativ to gain a foothold in hemophilia, the smaller company struck a licensing deal with Oxford BioMedica to develop and manufacture lentiviral vectors for the disease.

That deal is no more. After ending a previous development deal with the U.K.-based company last year—and as its own phase 3 program in hemophilia moves forward—Sanofi is pulling out of its remaining Oxford BioMedica collaboration.

Oxford BioMedica on Friday said Sanofi had decided to terminate the viral vector deal, first struck in February 2018. Under the original pact, potentially worth more than $100 million, Oxford BioMedica licensed its LentiVector Enabled tech to Bioverativ and allowed its partner access to its manufacturing know-how.

Sanofi had inked its Bioverativ buyout the prior month—in January 2018—and the buyout closed in March 2018. Bioverativ is a 2017 spinoff from Biogen.

Meanwhile, Sanofi has its own promising hemophilia A and B candidate in fitusiran. The company says the late-stage drug candidate has the “potential to transform the treatment of hemophilia.” The drug scored an FDA fast track designation last month.

Aside from the hemophilia collaboration it’s ending, Sanofi more than a decade ago licensed two gene therapy candidates from Oxford BioMedica. Without plans to move forward on those programs, the pharma company last year returned them to their original owner.

Under CEO Paul Hudson’s new “play to win” strategy, Sanofi is prioritizing development on pipeline candidates with the potential to change medical practice. The company has identified meds in cancer, hemophilia and multiple sclerosis, among other diseases, that fit the description, the CEO has said.

Aside from Oxford BioMedica’s work in gene therapy and hemophilia, the company has also jumped into the COVID-19 response. The company has partnered to scale up vaccine production with AstraZeneca as that drugmaker works to deliver on its goal to deliver billions of doses.

by Eric Sagonowsky

Source: fiercepharma.com

comments closed

Related News

January 23, 2022

UCB to acquire Zogenix

Life sciences

UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.

January 23, 2022

argenx announces VYVGART™ approval in Japan for the treatment of generalized myasthenia gravis

Life sciences

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved VYVGART™ (efgartigimod alfa) intravenous infusion for the treatment of adult patients with generalized myasthenia gravis (gMG) who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).

January 23, 2022

GlaxoSmithKline rejects Unilever’s $68B consumer health buyout offer, but a bigger bid is brewing

Life sciences

GSK has rejected three offers from Unilever to buy GSK’s consumer health unit, the company said Saturday. The latest offer from the fellow U.K. consumer goods giant, received Dec. 20 for a total value of 50 billion pounds ($68 billion), “fundamentally undervalued” the business and its prospects, GSK said.

Send this to a friend